



Ventripoint Announces Sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

Toronto, Ontario – The Newswire – April 25, 2023 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce its sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) being held on April 26th-29th 2023 in Dublin, Ireland.

The AEPC is a network of specialists in the paediatric and congenital cardiology field who strive to promote the sharing of information and resources within the community. The AEPC is currently one of the largest global associations in the cardiac field with over 1,000 paediatric cardiologists. We are excited to be part of this highly specialized group of people to demonstrate how our products enhance cardiac care.

This year's theme is "Building Bridges of Collaboration Across Europe In Congenital Cardiac Care". Ventripoint is very much part of this collaboration and is sponsoring an Industrial Symposium with PD Dr. med. Kai Thorsten Laser speaking about "Multi-Modality Assessment of the RV in Paediatric Heart Disease". In particular, he will speak about his use of the VMS+ and its importance in the management and care of patients. Dr. Laser is the Deputy Director and Senior Physician from the Department of Pediatric Cardiology and Congenital Heart Defects of Herz-und Diabeteszentrum North Rhine-Westfalia | HDZ. He is a leading cardiologist in the assessment of congenital heart disease using 2D/3D imaging. Assessment of right ventricular (RV) function is a challenge, especially in patients with congenital heart disease (CHD). Regular and accurate assessment of RV function is an integral part of diagnosing, planning treatment, and follow-up in such patients.

This year's conference and symposium are particularly notable for Ventripoint as we have transformed VMS+ into a product that offers a valuable solution that can be applied for daily use by our customers. Further, we are exhibiting (Booth 4) and are using this opportunity to continue to maintain our efforts to connect with clinicians within the global congenital cardiology community and to grow our reach globally. Our focus for this year is on sales as we have transitioned to a commercial operating company of which Europe is a particularly key market for the Ventripoint VMS+ products. Our products facilitate a more efficient patient journey by providing information about the structure and function of the heart with an accuracy equivalent to cardiac MRI at the time of the patient's first echo scan. This detailed information, very early on in the care journey, leads to improved quality of diagnosis, potentially shortening of the diagnosis time, and increasing efficacy of patient management and care.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients.

Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Mr. Jonathan Robinson
JRobinson@oakhillfinancial.ca
(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.